Federico M. Goodsaid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Federico M. Goodsaid has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Huixiao Hong
National Center for Toxicological Research, U.S. Food and Drug Administration
5 shared publications - James C. Fuscoe
Division of Systems Biology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA
5 shared publications - Leming Shi
National Center for Toxicological Research US Food and Drug Administration 3900 NCTR Road 72079 Jefferson AR USA
5 shared publications - Weida Tong
Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food & Drug Administration, Jefferson, AR 72079, USA
5 shared publications - Felix W. Frueh
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 1451 Rockville Pike, Rockville, Maryland 20852, USA
4 shared publications - Hong Fang
ICF International at FDA's National Center for Toxicological Research, 3900 NCTR Rd, Jefferson, AR 72079, USA
4 shared publications
Latest Publications
- 1 September 2010
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 2 (47) , 47ps44
Translational Medicine and the Value of Biomarker Qualification
The gap between development of exploratory biomarkers and their acceptance in drug development and regulatory review is a hurdle in the development of better therapies. The U.S. Food and Drug Administration has developed a regulatory process for biomarker qualification to accelerate the process by which new biomarkers are integrated in the development of therapies.
- 1 September 2010
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 2 (47) , 47ps44
Translational Medicine and the Value of Biomarker Qualification
The gap between development of exploratory biomarkers and their acceptance in drug development and regulatory review is a hurdle in the development of better therapies. The U.S. Food and Drug Administration has developed a regulatory process for biomarker qualification to accelerate the process by which new biomarkers are integrated in the development of therapies.
- Open Access
- 30 July 2010
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 10 (4) , 347-354
Assessment of variability in GWAS with CRLMM genotyping algorithm on WTCCC coronary artery disease
The robustness of genome-wide association study (GWAS) results depends on the genotyping algorithms used to establish the association. This paper initiated the assessment of the impact of the Corrected Robust Linear Model with Maximum Likelihood Classification (CRLMM) genotyping quality on identifying real significant genes in a GWAS with large sample sizes. With microarray image data from the Wellcome Trust Case–Control Consortium (WTCCC), 1991 individuals with coronary artery disease (CAD) and 1500 controls, genetic associations were evaluated under various batch sizes and compositions. Experimental designs included different batch sizes of 250, 350, 500, 2000 samples with different distributions of cases and controls in each batch with either randomized or simply combined (4:3 case–control ratios) or separate case–control samples as well as whole 3491 samples. The separate composition could create 2–3% discordance in the single nucleotide polymorphism (SNP) results for quality control/statistical analysis and might contribute to the lack of reproducibility between GWAS. CRLMM shows high genotyping accuracy and stability to batch effects. According to the genotypic and allelic tests (P−7), nine significant signals on chromosome 9 were found consistently in all batch sizes with combined design. Our findings are critical to optimize the reproducibility of GWAS and confirm the genetic role in the pathophysiology of CAD.
- 30 July 2010
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 10 (4) , 347-354
Open AccessAssessment of variability in GWAS with CRLMM genotyping algorithm on WTCCC coronary artery disease
The robustness of genome-wide association study (GWAS) results depends on the genotyping algorithms used to establish the association. This paper initiated the assessment of the impact of the Corrected Robust Linear Model with Maximum Likelihood Classification (CRLMM) genotyping quality on identifying real significant genes in a GWAS with large sample sizes. With microarray image data from the Wellcome Trust Case–Control Consortium (WTCCC), 1991 individuals with coronary artery disease (CAD) and 1500 controls, genetic associations were evaluated under various batch sizes and compositions. Experimental designs included different batch sizes of 250, 350, 500, 2000 samples with different distributions of cases and controls in each batch with either randomized or simply combined (4:3 case–control ratios) or separate case–control samples as well as whole 3491 samples. The separate composition could create 2–3% discordance in the single nucleotide polymorphism (SNP) results for quality control/statistical analysis and might contribute to the lack of reproducibility between GWAS. CRLMM shows high genotyping accuracy and stability to batch effects. According to the genotypic and allelic tests (P−7), nine significant signals on chromosome 9 were found consistently in all batch sizes with combined design. Our findings are critical to optimize the reproducibility of GWAS and confirm the genetic role in the pathophysiology of CAD.
- 1 June 2010
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 9 (6) , 435-445
Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact
Heterogeneity in the underlying mechanisms of disease processes and inter-patient variability in drug responses are major challenges in drug development. To address these challenges, biomarker strategies based on a range of platforms, such as microarray gene-expression technologies, are increasingly being applied to elucidate these sources of variability and thereby potentially increase drug development success rates. With the aim of enhancing understanding of the regulatory significance of such biomarker data by regulators and sponsors, the US Food and Drug Administration initiated a programme in 2004 to allow sponsors to submit exploratory genomic data voluntarily, without immediate regulatory impact. In this article, a selection of case studies from the first 5 years of this programme - which is now known as the voluntary exploratory data submission programme, and also involves collaboration with the European Medicines Agency - are discussed, and general lessons are highlighted.
- 1 June 2010
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 9 (6) , 435-445
Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact
Heterogeneity in the underlying mechanisms of disease processes and inter-patient variability in drug responses are major challenges in drug development. To address these challenges, biomarker strategies based on a range of platforms, such as microarray gene-expression technologies, are increasingly being applied to elucidate these sources of variability and thereby potentially increase drug development success rates. With the aim of enhancing understanding of the regulatory significance of such biomarker data by regulators and sponsors, the US Food and Drug Administration initiated a programme in 2004 to allow sponsors to submit exploratory genomic data voluntarily, without immediate regulatory impact. In this article, a selection of case studies from the first 5 years of this programme - which is now known as the voluntary exploratory data submission programme, and also involves collaboration with the European Medicines Agency - are discussed, and general lessons are highlighted.
- 1 May 2010
- Published by Springer Nature in Nature Biotechnology
- Vol. 28 (5) , 441-443
Evolution of biomarker qualification at the health authorities
- 1 May 2010
- Published by Springer Nature in Nature Biotechnology
- Vol. 28 (5) , 441-443
Evolution of biomarker qualification at the health authorities
- 30 October 2009
- Published by Wiley
- p. 191-201
Potential Sources of Spurious Associations and Batch Effects in Genome‐Wide Association Studies
- 30 October 2009
- Published by Wiley
- p. 191-201
Potential Sources of Spurious Associations and Batch Effects in Genome‐Wide Association Studies
- 26 August 2009
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 86 (5) , 490-496
Novel Biomarkers of Acute Kidney Toxicity
Novel biomarkers of kidney toxicity are powerful tools not only with respect to their clinical applications but also because of their impact on drug development. These biomarkers can influence the assessment of efficacy of new drugs for kidney diseases as well as the risk management for new drugs. The science behind these novel biomarkers reflects the evolution over the past decade of genomic and proteomic platforms that have transformed the discovery and development of new biomarkers for preclinical and clinical applications in drug development. Several of these biomarkers are in use as transcriptomic biomarkers in animal models as well as translational proteomic biomarkers in animal models and in humans. Their ability to detect kidney damage earlier than is possible with currently accessible biomarkers is being given qualification through regulatory biomarker‐qualification programs, which will help establish consensus for their widespread use. Clinical Pharmacology & Therapeutics (2009) 86 5, 490–496. doi:10.1038/clpt.2009.149
- 26 August 2009
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 86 (5) , 490-496
Novel Biomarkers of Acute Kidney Toxicity
Novel biomarkers of kidney toxicity are powerful tools not only with respect to their clinical applications but also because of their impact on drug development. These biomarkers can influence the assessment of efficacy of new drugs for kidney diseases as well as the risk management for new drugs. The science behind these novel biomarkers reflects the evolution over the past decade of genomic and proteomic platforms that have transformed the discovery and development of new biomarkers for preclinical and clinical applications in drug development. Several of these biomarkers are in use as transcriptomic biomarkers in animal models as well as translational proteomic biomarkers in animal models and in humans. Their ability to detect kidney damage earlier than is possible with currently accessible biomarkers is being given qualification through regulatory biomarker‐qualification programs, which will help establish consensus for their widespread use. Clinical Pharmacology & Therapeutics (2009) 86 5, 490–496. doi:10.1038/clpt.2009.149
- 1 December 2008
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 28 (12) , 1423-1424
Modulation of Clopidogrel Pharmacodynamic Response
- 1 December 2008
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 28 (12) , 1423-1424
Modulation of Clopidogrel Pharmacodynamic Response
- Open Access
- 12 August 2008
- Published by Springer Nature in BMC Bioinformatics
- Vol. 9 (S9) , S10
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies
Reproducibility is a fundamental requirement in scientific experiments. Some recent publications have claimed that microarrays are unreliable because lists of differentially expressed genes (DEGs) are not reproducible in similar experiments. Meanwhile, new statistical methods for identifying DEGs continue to appear in the scientific literature. The resultant variety of existing and emerging methods exacerbates confusion and continuing debate in the microarray community on the appropriate choice of methods for identifying reliable DEG lists.
- 12 August 2008
- Published by Springer Nature in BMC Bioinformatics
- Vol. 9 (S9) , S10
Open AccessThe balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies
Reproducibility is a fundamental requirement in scientific experiments. Some recent publications have claimed that microarrays are unreliable because lists of differentially expressed genes (DEGs) are not reproducible in similar experiments. Meanwhile, new statistical methods for identifying DEGs continue to appear in the scientific literature. The resultant variety of existing and emerging methods exacerbates confusion and continuing debate in the microarray community on the appropriate choice of methods for identifying reliable DEG lists.
- Open Access
- 1 March 2008
- Published by Elsevier in Toxicology
- Vol. 245 (3) , 219-223
Strategic paths for biomarker qualification
- 1 March 2008
- Published by Elsevier in Toxicology
- Vol. 245 (3) , 219-223
Open AccessStrategic paths for biomarker qualification
- 13 June 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (5) , 354-358
Implementing the U.S. FDA guidance on pharmacogenomic data submissions
The FDA Guidance for Industry: Pharmacogenomics Data Submissions was issued in 2005. This guidance document covers a broad area associated with how and when to submit genomic data to the FDA. Additional tasks associated with genomic data submissions include the implementation of genomic data submissions; the process for qualification of exploratory biomarkers into valid biomarkers; and technical recommendations for the generation and submission of genomic data to the FDA. These tasks have been addressed throughout the past 2 years by a number of initiatives. These initiatives have included the development of the Interdisciplinary Pharmacogenomics Review Group for review of pharmacogenomic data submissions, the pilot process for qualification of biomarkers, and the concept paper on recommendations for the generation and submission of genomic data. These initiatives have contributed to the effective implementation of the Pharmacogenomics Guidance at the FDA. Environ. Mol. Mutagen. 48:354–358, Published 2007 Wiley‐Liss, Inc.
- 13 June 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (5) , 354-358
Implementing the U.S. FDA guidance on pharmacogenomic data submissions
The FDA Guidance for Industry: Pharmacogenomics Data Submissions was issued in 2005. This guidance document covers a broad area associated with how and when to submit genomic data to the FDA. Additional tasks associated with genomic data submissions include the implementation of genomic data submissions; the process for qualification of exploratory biomarkers into valid biomarkers; and technical recommendations for the generation and submission of genomic data to the FDA. These tasks have been addressed throughout the past 2 years by a number of initiatives. These initiatives have included the development of the Interdisciplinary Pharmacogenomics Review Group for review of pharmacogenomic data submissions, the pilot process for qualification of biomarkers, and the concept paper on recommendations for the generation and submission of genomic data. These initiatives have contributed to the effective implementation of the Pharmacogenomics Guidance at the FDA. Environ. Mol. Mutagen. 48:354–358, Published 2007 Wiley‐Liss, Inc.